Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00004771
NCT00004771
Completed
Phase 2

Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease

National Center for Research Resources (NCRR)0 sites40 target enrollmentOctober 1992
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSpinal Muscular AtrophyAmyotrophic Lateral SclerosisSpinobulbar Muscular Atrophy
Drugsleuprolidetestosterone

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Spinal Muscular Atrophy
Sponsor
National Center for Research Resources (NCRR)
Enrollment
40
Status
Completed
Last Updated
20 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

OBJECTIVES:

I. Evaluate the effects of androgen suppression with leuprolide and androgen replacement with testosterone enanthate on muscle strength in men with Kennedy's disease or other motor neuron disease.

Detailed Description

PROTOCOL OUTLINE: All patients receive androgen suppression with leuprolide acetate injections every 4 weeks for 6 months, plus hormone replacement therapy with testosterone enanthate injections every week for 24 weeks.

Registry
clinicaltrials.gov
Start Date
October 1992
End Date
TBD
Last Updated
20 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
National Center for Research Resources (NCRR)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Phase 2
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical ProstatectomyProstate AdenocarcinomaStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate Cancer
NCT00937768Mayo Clinic16
Unknown
Phase 2
Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-EffectsBreast CancerArthralgiaOsteoporosis
NCT00497458Havah Therapeutics Pty Ltd90
Active, not recruiting
Phase 2
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsAdult Ovarian Granulosa Cell Tumor
NCT06169124National Cancer Institute (NCI)37
Active, not recruiting
Phase 2
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerMetastatic Prostate AdenocarcinomaProstate Adenocarcinoma With Focal Neuroendocrine DifferentiationRecurrent Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
NCT03902951Jonsson Comprehensive Cancer Center28
Completed
Phase 3
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner SyndromeTurner Syndrome
NCT00029159Thomas Jefferson University200